Argenx CIDP Data Set To Attract Big Pharma Suitors

Pipeline-In-A-Product Vyvgart Sweeps Through Another Phase III

The very positive Vyvgart ADHERE data in chronic inflammatory demyelinating polyneuropathy, the recent approval for the subcutaneous version for generalized myasthenia gravis and the drug's already strong sales mean that Argenx will again be at the top of the M&A targets tree.

Lions
On the prowl: Pharma's big cats are looking for assets • Source: Shutterstock

argenx N.V.'s position as one of the crown jewels of the European biotech sector, and a rumored takeover target for big pharma, has been enhanced by positive late-stage data on its pipeline-in-a-product Vyvgart in chronic inflammatory demyelinating polyneuropathy (CIDP).

The Belgian-Dutch group has unveiled topline results from the Phase III ADHERE study evaluating the subcutaneous version of the drug,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.